Global Immunosuppressant Drugs Market by Function (Autoimmune Diseases, Organ Transplant), Drug Class (Antiproliferative Agent, Calcineurin Inhibitor, mTOR Inhibitor), Route of Administration, End User - Forecast 2024-2030- Product Image

Sale

Global Immunosuppressant Drugs Market by Function (Autoimmune Diseases, Organ Transplant), Drug Class (Antiproliferative Agent, Calcineurin Inhibitor, mTOR Inhibitor), Route of Administration, End User - Forecast 2024-2030

Report
197 Pages
March 2024
Region: Global
360iResearch™
ID: 5014103

UP TO €846EUR$875USD£727GBP OFF until Dec 31^st 2024

The Immunosuppressant Drugs Market size was estimated at USD 1.11 billion in 2023, USD 1.18 billion in 2024, and is expected to grow at a CAGR of 6.36% to reach USD 1.71 billion by 2030.

FPNV Positioning Matrix

The FPNV Positioning Matrix is pivotal in evaluating the Immunosuppressant Drugs Market. It offers a comprehensive assessment of vendors, examining key metrics related to Business Strategy and Product Satisfaction. This in-depth analysis empowers users to make well-informed decisions aligned with their requirements. Based on the evaluation, the vendors are then categorized into four distinct quadrants representing varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital (V).

Market Share Analysis

The Market Share Analysis is a comprehensive tool that provides an insightful and in-depth examination of the current state of vendors in the Immunosuppressant Drugs Market. By meticulously comparing and analyzing vendor contributions in terms of overall revenue, customer base, and other key metrics, we can offer companies a greater understanding of their performance and the challenges they face when competing for market share. Additionally, this analysis provides valuable insights into the competitive nature of the sector, including factors such as accumulation, fragmentation dominance, and amalgamation traits observed over the base year period studied. With this expanded level of detail, vendors can make more informed decisions and devise effective strategies to gain a competitive edge in the market.

Key Company Profiles

The report delves into recent significant developments in the Immunosuppressant Drugs Market, highlighting leading vendors and their innovative profiles. These include AbbVie Inc., Amgen Inc., Astellas Pharma Inc., Cadila Healthcare Ltd., F. Hoffmann-La Roche Ltd., GlaxoSmithKline PLC, Glenmark Pharmaceuticals Limited, Intas Pharmaceuticals Ltd., Novartis AG, Pfizer Inc., Sanofi S.A., Sebela Pharmaceuticals, Teva Pharmaceuticals Industries Ltd., Thermo Fisher Scientific Inc., and Viatris Inc.

Market Segmentation & Coverage

This research report categorizes the Immunosuppressant Drugs Market to forecast the revenues and analyze trends in each of the following sub-markets:

Function
- Autoimmune Diseases
  - Localized Autoimmune Disease
  - Systemic Autoimmune Disease
- Organ Transplant
Drug Class
- Antiproliferative Agent
- Calcineurin Inhibitor
- mTOR Inhibitor
- Steroid
Route of Administration
- Intravenous
- Oral
End User
- Clinic
- Hospital
- Old Age Home
- Organ Transplant Center
- Rehabilitation Center

Region
- Americas
  - Argentina
  - Brazil
  - Canada
  - Mexico
  - United States
    - California
    - Florida
    - Illinois
    - New York
    - Ohio
    - Pennsylvania
    - Texas
- Asia-Pacific
  - Australia
  - China
  - India
  - Indonesia
  - Japan
  - Malaysia
  - Philippines
  - Singapore
  - South Korea
  - Taiwan
  - Thailand
  - Vietnam
- Europe, Middle East & Africa
  - Denmark
  - Egypt
  - Finland
  - France
  - Germany
  - Israel
  - Italy
  - Netherlands
  - Nigeria
  - Norway
  - Poland
  - Qatar
  - Russia
  - Saudi Arabia
  - South Africa
  - Spain
  - Sweden
  - Switzerland
  - Turkey
  - United Arab Emirates
  - United Kingdom

The report offers valuable insights on the following aspects:

Market Penetration: It presents comprehensive information on the market provided by key players.
Market Development: It delves deep into lucrative emerging markets and analyzes the penetration across mature market segments.
Market Diversification: It provides detailed information on new product launches, untapped geographic regions, recent developments, and investments.
Competitive Assessment & Intelligence: It conducts an exhaustive assessment of market shares, strategies, products, certifications, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players.
Product Development & Innovation: It offers intelligent insights on future technologies, R&D activities, and breakthrough product developments.

The report addresses key questions such as:

What is the market size and forecast of the Immunosuppressant Drugs Market?
Which products, segments, applications, and areas should one consider investing in over the forecast period in the Immunosuppressant Drugs Market?
What are the technology trends and regulatory frameworks in the Immunosuppressant Drugs Market?
What is the market share of the leading vendors in the Immunosuppressant Drugs Market?
Which modes and strategic moves are suitable for entering the Immunosuppressant Drugs Market?

Please note: For this report, the purchase of an Enterprise license allows up to ten worldwide users of an organization access to the report

Please note: This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.

With the purchase of this report at the Multi-user License or greater level, you will have access to one hour with an expert analyst who will help you link key findings in the report to the business issues you're addressing. This will need to be used within three months of purchase.

This report also includes a complimentary Excel file with data from the report for purchasers at the Site License or greater level.

1. Preface

1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders

2. Research Methodology

2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

4.1. Introduction
4.2. Immunosuppressant Drugs Market, by Region

5. Market Insights

5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Increasing prevalence of autoimmune disease due to changing lifestyles
5.1.1.2. Growing number of organ transplantation procedures for lungs, kidneys, liver, pancreas, and other
5.1.1.3. Improvements in tissue engineering and organ transplantations
5.1.2. Restraints
5.1.2.1. Complicated regulatory processes
5.1.3. Opportunities
5.1.3.1. Development of novel drug therapies
5.1.3.2. Recent advances in immuno-oncology and regulatory approvals
5.1.4. Challenges
5.1.4.1. Complications associated with the personalizing immunosuppressive therapy
5.2. Market Segmentation Analysis
5.3. Market Trend Analysis
5.4. Cumulative Impact of COVID-19
5.5. Cumulative Impact of Russia-Ukraine Conflict
5.6. Cumulative Impact of High Inflation
5.7. Porter’s Five Forces Analysis
5.7.1. Threat of New Entrants
5.7.2. Threat of Substitutes
5.7.3. Bargaining Power of Customers
5.7.4. Bargaining Power of Suppliers
5.7.5. Industry Rivalry
5.8. Value Chain & Critical Path Analysis
5.9. Regulatory Framework
5.10. Client Customization

6. Immunosuppressant Drugs Market, by Function

6.1. Introduction
6.2. Autoimmune Diseases
6.3.1. Localized Autoimmune Disease
6.3.2. Systemic Autoimmune Disease
6.3. Organ Transplant

7. Immunosuppressant Drugs Market, by Drug Class

7.1. Introduction
7.2. Antiproliferative Agent
7.3. Calcineurin Inhibitor
7.4. mTOR Inhibitor
7.5. Steroid

8. Immunosuppressant Drugs Market, by Route of Administration

8.1. Introduction
8.2. Intravenous
8.3. Oral

9. Immunosuppressant Drugs Market, by End User

9.1. Introduction
9.2. Clinic
9.3. Hospital
9.4. Old Age Home
9.5. Organ Transplant Center
9.6. Rehabilitation Center

10. Americas Immunosuppressant Drugs Market

10.1. Introduction
10.2. Argentina
10.3. Brazil
10.4. Canada
10.5. Mexico
10.6. United States

11. Asia-Pacific Immunosuppressant Drugs Market

11.1. Introduction
11.2. Australia
11.3. China
11.4. India
11.5. Indonesia
11.6. Japan
11.7. Malaysia
11.8. Philippines
11.9. Singapore
11.10. South Korea
11.11. Taiwan
11.12. Thailand
11.13. Vietnam

12. Europe, Middle East & Africa Immunosuppressant Drugs Market

12.1. Introduction
12.2. Denmark
12.3. Egypt
12.4. Finland
12.5. France
12.6. Germany
12.7. Israel
12.8. Italy
12.9. Netherlands
12.10. Nigeria
12.11. Norway
12.12. Poland
12.13. Qatar
12.14. Russia
12.15. Saudi Arabia
12.16. South Africa
12.17. Spain
12.18. Sweden
12.19. Switzerland
12.20. Turkey
12.21. United Arab Emirates
12.22. United Kingdom

13. Competitive Landscape

13.1. FPNV Positioning Matrix
13.2. Market Share Analysis, By Key Player
13.3. Competitive Scenario Analysis, By Key Player

14. Competitive Portfolio

14.1. Key Company Profiles
14.1.1. AbbVie Inc.
14.1.2. Amgen Inc.
14.1.3. Astellas Pharma Inc.
14.1.4. Cadila Healthcare Ltd.
14.1.5. F. Hoffmann-La Roche Ltd.
14.1.6. GlaxoSmithKline PLC
14.1.7. Glenmark Pharmaceuticals Limited
14.1.8. Intas Pharmaceuticals Ltd.
14.1.9. Novartis AG
14.1.10. Pfizer Inc.
14.1.11. Sanofi S.A.
14.1.12. Sebela Pharmaceuticals
14.1.13. Teva Pharmaceuticals Industries Ltd.
14.1.14. Thermo Fisher Scientific Inc.
14.1.15. Viatris Inc.
14.2. Key Product Portfolio

15. Appendix

15.1. Discussion Guide
15.2. License & Pricing

List of Figures

FIGURE 1. IMMUNOSUPPRESSANT DRUGS MARKET RESEARCH PROCESS
FIGURE 2. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2022 VS 2030
FIGURE 3. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
FIGURE 4. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
FIGURE 5. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 6. IMMUNOSUPPRESSANT DRUGS MARKET DYNAMICS
FIGURE 7. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2022 VS 2030 (%)
FIGURE 8. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 9. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2030 (%)
FIGURE 10. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 11. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2030 (%)
FIGURE 12. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 13. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2022 VS 2030 (%)
FIGURE 14. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 15. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 16. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 17. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2022 VS 2030 (%)
FIGURE 18. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 19. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 20. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 21. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2030 (%)
FIGURE 22. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
FIGURE 23. IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
FIGURE 24. IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2022

List of Tables

TABLE 1. IMMUNOSUPPRESSANT DRUGS MARKET SEGMENTATION & COVERAGE
TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
TABLE 3. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, 2018-2030 (USD MILLION)
TABLE 4. GLOBAL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
TABLE 5. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 6. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, BY REGION, 2018-2030 (USD MILLION)
TABLE 7. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 8. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY LOCALIZED AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 9. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY SYSTEMIC AUTOIMMUNE DISEASE, BY REGION, 2018-2030 (USD MILLION)
TABLE 10. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORGAN TRANSPLANT, BY REGION, 2018-2030 (USD MILLION)
TABLE 11. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 12. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ANTIPROLIFERATIVE AGENT, BY REGION, 2018-2030 (USD MILLION)
TABLE 13. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY CALCINEURIN INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 14. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY MTOR INHIBITOR, BY REGION, 2018-2030 (USD MILLION)
TABLE 15. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STEROID, BY REGION, 2018-2030 (USD MILLION)
TABLE 16. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 17. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY INTRAVENOUS, BY REGION, 2018-2030 (USD MILLION)
TABLE 18. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 19. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 20. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY CLINIC, BY REGION, 2018-2030 (USD MILLION)
TABLE 21. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY HOSPITAL, BY REGION, 2018-2030 (USD MILLION)
TABLE 22. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY OLD AGE HOME, BY REGION, 2018-2030 (USD MILLION)
TABLE 23. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ORGAN TRANSPLANT CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 24. IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY REHABILITATION CENTER, BY REGION, 2018-2030 (USD MILLION)
TABLE 25. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 26. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 27. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 28. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 29. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 30. AMERICAS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 31. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 32. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 33. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 34. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 35. ARGENTINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 36. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 37. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 38. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 39. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 40. BRAZIL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 41. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 42. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 43. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 44. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 45. CANADA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 46. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 47. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 48. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 49. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 50. MEXICO IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 51. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 52. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 53. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 54. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 55. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 56. UNITED STATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
TABLE 57. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 58. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 59. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 60. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 61. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 62. ASIA-PACIFIC IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 63. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 64. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 65. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 66. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 67. AUSTRALIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 68. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 69. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 70. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 71. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 72. CHINA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 73. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 74. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 75. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 76. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 77. INDIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 78. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 79. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 80. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 81. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 82. INDONESIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 83. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 84. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 85. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 86. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 87. JAPAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 88. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 89. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 90. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 91. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 92. MALAYSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 93. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 94. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 95. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 96. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 97. PHILIPPINES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 98. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 99. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 100. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 101. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 102. SINGAPORE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 103. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 104. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 105. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 106. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 107. SOUTH KOREA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 108. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 109. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 110. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 111. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 112. TAIWAN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 113. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 114. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 115. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 116. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 117. THAILAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 118. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 119. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 120. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 121. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 122. VIETNAM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 123. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 124. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 125. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 126. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 127. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 128. EUROPE, MIDDLE EAST & AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
TABLE 129. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 130. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 131. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 132. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 133. DENMARK IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 134. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 135. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 136. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 137. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 138. EGYPT IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 139. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 140. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 141. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 142. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 143. FINLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 144. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 145. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 146. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 147. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 148. FRANCE IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 149. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 150. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 151. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 152. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 153. GERMANY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 154. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 155. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 156. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 157. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 158. ISRAEL IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 159. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 160. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 161. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 162. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 163. ITALY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 164. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 165. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 166. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 167. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 168. NETHERLANDS IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 169. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 170. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 171. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 172. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 173. NIGERIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 174. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 175. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 176. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 177. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 178. NORWAY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 179. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 180. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 181. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 182. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 183. POLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 184. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 185. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 186. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 187. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 188. QATAR IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 189. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 190. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 191. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 192. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 193. RUSSIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 194. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 195. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 196. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 197. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 198. SAUDI ARABIA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 199. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 200. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 201. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 202. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 203. SOUTH AFRICA IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 204. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 205. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 206. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 207. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 208. SPAIN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 209. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 210. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 211. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 212. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 213. SWEDEN IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 214. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 215. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 216. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 217. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 218. SWITZERLAND IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 219. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 220. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 221. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 222. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 223. TURKEY IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 224. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 225. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 226. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 227. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 228. UNITED ARAB EMIRATES IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 229. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
TABLE 230. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY AUTOIMMUNE DISEASES, 2018-2030 (USD MILLION)
TABLE 231. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY DRUG CLASS, 2018-2030 (USD MILLION)
TABLE 232. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY ROUTE OF ADMINISTRATION, 2018-2030 (USD MILLION)
TABLE 233. UNITED KINGDOM IMMUNOSUPPRESSANT DRUGS MARKET SIZE, BY END USER, 2018-2030 (USD MILLION)
TABLE 234. IMMUNOSUPPRESSANT DRUGS MARKET, FPNV POSITIONING MATRIX, 2022
TABLE 235. IMMUNOSUPPRESSANT DRUGS MARKET SHARE, BY KEY PLAYER, 2022
TABLE 236. IMMUNOSUPPRESSANT DRUGS MARKET LICENSE & PRICING

Companies Mentioned

AbbVie Inc.
Amgen Inc.
Astellas Pharma Inc.
Cadila Healthcare Ltd.
F. Hoffmann-La Roche Ltd.
GlaxoSmithKline PLC
Glenmark Pharmaceuticals Limited
Intas Pharmaceuticals Ltd.
Novartis AG
Pfizer Inc.
Sanofi S.A.
Sebela Pharmaceuticals
Teva Pharmaceuticals Industries Ltd.
Thermo Fisher Scientific Inc.
Viatris Inc.

Methodology

LOADING...

Table Information

Report Attribute	Details
No. of Pages	197
Published	March 2024
Forecast Period	2024 - 2030
Estimated Market Value ( USD ) in 2024	$ 1.18 Billion
Forecasted Market Value ( USD ) by 2030	$ 1.71 Billion
Compound Annual Growth Rate	6.3%
Regions Covered	Global
No. of Companies Mentioned	15

PURCHASE OPTIONS

Single User License Online Access - 1 Year

Single User License PDF, Excel And Online Access - 1 Year

1 - 5 User License PDF, Excel And Online Access - 1 Year

Site License PDF, Excel And Online Access - 1 Year

Enterprise License PDF, Excel And Online Access - 1 Year

need a quote ?

License	Format	Properties	Price
SINGLE USER LICENSE Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€3262EUR$3,374USD£2,802GBP €3624EUR$3,749USD£3,113GBP
SINGLE USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a single user license, allowing one user access to the product.	€4132EUR$4,274USD£3,549GBP €4591EUR$4,749USD£3,944GBP
1 - 5 USER LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a 1-5 user license, allowing up to five users have access to the product.	€5002EUR$5,174USD£4,297GBP €5558EUR$5,749USD£4,774GBP
SITE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is a site license, allowing all users within a given geographical location of your organization access to the product.	€5872EUR$6,074USD£5,044GBP €6525EUR$6,749USD£5,605GBP
ENTERPRISE LICENSE PDF, Excel and Online Access - 1 Year	The product can be accessed through a secure website. Username and password will be sent via email. The access period is one year.	This is an enterprise license, allowing all employees within your organization access to the product.	€7613EUR$7,874USD£6,539GBP €8458EUR$8,749USD£7,265GBP

FPNV Positioning Matrix

Market Share Analysis

Key Company Profiles

Market Segmentation & Coverage

The report offers valuable insights on the following aspects:

The report addresses key questions such as:

Table of Contents

Companies Mentioned

Methodology

Table Information

Related Topics

Related Reports

Immunosuppressants - Global Strategic Business Report

Organ Transplant Immunosuppressant Drugs - Global Strategic Business Report

Global Organ Transplant Immunosuppressant Drugs Market by Drug Class (Antibodies, Antiproliferative Agents, Calcineurin Inhibitors), Transplant Type (Heart, Kidney, Liver), Distribution Channel - Forecast 2024-2030

Immunosuppressants Global Market Report 2024

Global Immunosuppressant Drugs Market (2023-2028) Competitive Analysis, Impact of Covid-19, Ansoff Analysis